Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from genetic, metabolic, and severe, life-threatening conditions, with operations spanning Australia, Europe, the United States, Switzerland, and various international markets. The company's flagship product is SCENESSE, a systemic photoprotective medication. This drug is specifically designed to prevent light-induced damage in adult individuals diagnosed with erythropoietic protoporphyria (EPP). Beyond its established product, Clinuvel's development pipeline encompasses several other promising compounds. These include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which is recognized for its ability to provoke heightened and sustained cellular activity; and PRÉNUMBRA, an injectable liquid formulation of afamelanotide. Furthermore, Clinuvel has forged a strategic partnership with HK Winhealth Pharma Group Co. Limited. This collaboration aims to provide SCENESSE to EPP patients in the People's Republic of China via a dedicated named patient program.
—
Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from genetic, metabolic, and severe, life-threatening conditions, with operations spanning Australia, Europe, the United States, Switzerland, and various international markets. The company's flagship product is SCENESSE, a systemic photoprotective medication. This drug is specifically designed to prevent light-induced damage in adult individuals diagnosed with erythropoietic protoporphyria (EPP). Beyond its established product, Clinuvel's development pipeline encompasses several other promising compounds. These include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which is recognized for its ability to provoke heightened and sustained cellular activity; and PRÉNUMBRA, an injectable liquid formulation of afamelanotide. Furthermore, Clinuvel has forged a strategic partnership with HK Winhealth Pharma Group Co. Limited. This collaboration aims to provide SCENESSE to EPP patients in the People's Republic of China via a dedicated named patient program.
—
Daily adjusted close
Clinuvel Pharmaceuticals Limited (CLVLF), an Australian biopharmaceutical firm established in Melbourne in 1987, specializes in the creation and global marketing of therapeutic solutions. Its primary focus is on patients suffering from genetic, metabolic, and severe, life-threatening conditions, with operations spanning Australia, Europe, the United States, Switzerland, and various international markets. The company's flagship product is SCENESSE, a systemic photoprotective medication. This drug is specifically designed to prevent light-induced damage in adult individuals diagnosed with erythropoietic protoporphyria (EPP). Beyond its established product, Clinuvel's development pipeline encompasses several other promising compounds. These include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which is recognized for its ability to provoke heightened and sustained cellular activity; and PRÉNUMBRA, an injectable liquid formulation of afamelanotide. Furthermore, Clinuvel has forged a strategic partnership with HK Winhealth Pharma Group Co. Limited. This collaboration aims to provide SCENESSE to EPP patients in the People's Republic of China via a dedicated named patient program.